27 February 2026 12:57
Topic starter
2
Does psilocybin or psilocin increase bioavailable tryptophan? Could this have an antidepressant effect? After all, you need tryptophan to produce serotonin, and if you have too little of it, you become depressed. If less tryptophan is converted to kynurenine, relatively more remains available for serotonin synthesis.
1 Answer
1
27 February 2026 13:12
The short answer is: Yes, in theory your logic is completely correct. In neuroscience, we call this the prevention of the "Tryptophan Steal".
The Tryptophan Robbery: How stress "sets" your happiness hormone"
Tryptophan is an essential amino acid that your body can use for two main purposes. The first is the production of serotonin (), what you need to feel stable and happy. The second is the Kynurenine route.
Under normal circumstances, only a small portion goes to kynurenine. But as soon as your body signals a "burn" due to, for example, chronic stress, an unhealthy gut flora, or low-grade inflammation, the following happens:
-
Activation of IDO/TDO: Stress hormones (cortisol) and inflammatory substances (such as and ) convert the enzymes IDO and TDO on high alert.
-
The diversion: These enzymes draw almost all available tryptophan into the kynurenine pathway.
-
The result: Simply too little tryptophan remains for the production of serotonin. You become "chemically exhausted," which manifests as depression, anxiety, and brain fog.
Psilocybin as the "Fire Extinguisher""
Psilocybin (or actually the active form) psilocin) does more than just give you a psychedelic experience. It intervenes directly in this process:
-
Inhibition of theft: Psilocin binds to the -receptors, which are also located on your immune cells. Research suggests that this the production of those inflammatory substances ( and ) can brake.
-
The "System reset": As inflammatory markers decrease, IDO and TDO become less active. The "roof" stops, suddenly making more tryptophan available again for the natural production of serotonin.
-
Neuroplasticity: In addition to this biochemical shift, psilocybin also stimulates the production of BDNF (Brain-Derived Neurotrophic Factor), a kind of "fertilizer" for your brain that helps to make new connections.
Is this the secret of the antidepressant effect?
The antidepressant effect of psilocybin is probably a combination of factors. On the one hand, there is the psychological breakthrough during the session, but on the other hand, there is this biological "maintenance".
By normalizing the tryptophan balance, the brain once again receives the raw materials it needs to independently maintain a healthy mood. It is as if you are not only restoring the software of a computer (the psyche), but also repairing the power supply (tryptophan availability).
The caveat: Although the theory works, it is still difficult to demonstrate this directly in the blood of humans. This is because most people in clinical studies are "healthy" in terms of inflammation, leaving little to repair. The real gain likely lies with the group of people for whom that chronic inflammation (and thus tryptophan depletion) is the root cause of their depression.
Spoiler
Research
Available research indicates that psilocybin can indirectly influence the availability of tryptophan for serotonin synthesis by lowering stress and inflammation levels. Consequently, activation of the kynurenine pathway is likely inhibited, leaving more tryptophan available for serotonin synthesis. Key points from the literature are: Stress and inflammation direct tryptophan to the kynurenine pathway: Cortisol and other stress hormones upregulate the liver enzyme tryptophan-2,3-dioxygenase (TDO); pro-inflammatory cytokines (IFN-γ, TNF-α, IL-6) induce indoleamine-2,3-dioxygenase (IDO). This increases the conversion of tryptophan to kynurenine and reduces the amount of tryptophan available for serotonin synthesis. This mechanism is observed in stress, inflammation, leaky gut, and psychiatric disorders. In vitro studies demonstrate anti-inflammatory effects of psilocin/psilocybin: In a mouse model with LPS-activated macrophages, psilocin (the active metabolite of psilocybin) reduced TNF-α secretion more strongly than psilocybin; psilocin also increased IL-10 in post-treatment conditions, indicating an anti-inflammatory response. In a human THP-1 macrophage lineage, psilocybin influenced the expression of inflammatory markers depending on the dose: 10 µM and 15 µM reduced Cox-2 protein levels, 10 µM moderated IL-6, while 15 µM increased IL-6; some concentrations also altered Pro-TNF-α. These studies suggest that psilocybin/psilocin may inhibit inflammatory pathways such as NF-κB and IL-6/JAK/STAT signaling pathways, but the effects are dose- and context-dependent. The effect in the human body has been demonstrated to a limited extent: An open-label study with 16 healthy volunteers (0.2–0.3 mg/kg psilocybin) measured high-sensitivity C-reactive protein (hs-CRP), TNF-α, and soluble urokinase plasminogen activator receptor (suPAR) before and one day after administration. No significant changes in these inflammatory biomarkers were found. The authors conclude that single-dose psilocybin administration in healthy individuals is not sufficient to lower peripheral inflammatory markers. Hypothetical link with tryptophan distribution: Because stress and inflammation activate the kynurenine pathway, a reduction of these factors via psilocybin therapy could ensure that less tryptophan is converted into kynurenine via IDO/TDO. Consequently, relatively more tryptophan would remain available for serotonin synthesis. In vitro results show that psilocybin/psilocin can dampen inflammatory processes, but evidence in humans is scarce, and the first study found no effect on hs-CRP or TNF-α. Conclusion: The theory that psilocybin influences tryptophan distribution by reducing stress and inflammatory processes is biochemically plausible. Stress hormones and pro-inflammatory cytokines activate IDO/TDO, which directs tryptophan to the kynurenine pathway. Preclinical studies show that psilocybin/psilocin can lower inflammatory markers such as TNF-α and IL-6 in immune cells. This would reduce IDO activity and free up more tryptophan for serotonin. However, to date, clinical studies in healthy individuals have not demonstrated a clear decrease in peripheral inflammatory markers. Therefore, there is no direct evidence yet that psilocybin therapy inhibits the kynurenine pathway in humans; future research must investigate long-term treatments, central markers of neuroinflammation, and clinical populations to confirm this mechanism.